天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (7): 616-620.doi: 10.11958/20192718

• 细胞与分子生物学 • 上一篇    下一篇

基于TCGA数据库筛选结直肠肿瘤K-RAS突变相关lincRNA

白雪，贺平△   

  1. 西南医科大学中西医结合学院（邮编 646000）
  • 收稿日期:2019-09-02 修回日期:2020-04-30 出版日期:2020-07-15 发布日期:2020-07-16
  • 作者简介:白雪（1990），女，硕士在读，住院医师，主要从事肛肠外科临床与基础研究

Screening of K-RAS mutation related lincRNA in colorectal carcinoma based on TCGA database

BAI Xue, HE Ping△   

  1. College of Integrated Traditional Chinese and Western Medicine, Southwestern Medical University, Luzhou 646000, China
  • Received:2019-09-02 Revised:2020-04-30 Published:2020-07-15 Online:2020-07-16

PDF (PC)

5981

摘要： 目的 筛选结肠直肠癌（CRC）中与鼠类肉瘤病毒癌基因 K-RAS 突变相关的基因间长链非编码 RNA （lincRNA）。方法 使用来自癌症基因组图谱（TCGA）的RNA-Seq和临床数据来鉴定CRC中与K-RAS突变相关的 lincRNA。受试者工作特征（ROC）曲线分析差异表达的lincRNA与K-RAS野生型或突变型CRC 5年和10年生存率的 关系，筛选关键的lincRNA。通过Kaplan-Meier生存曲线分析关键lincRNA表达对患者5年和10年生存率的影响，同 时分析关键lincRNA 与患者临床特征的关系。结果 共分析了585个癌组织和51个正常组织样品的RNA-Seq 数 据。从数据中获得6 452个lincRNA，其中有85个上调，40个下调。筛选出12个在K-RAS突变CRC中差异表达的 lincRNA，其中 AL390719.2 为具有 K-RAS 突变的关键 lincRNA。生存分析结果显示，在 K-RAS 突变型中 lincRNA AL390719.2 表达与患者 10 年生存率（Log -rank χ2 =10.740，HR=3.255，P=0.002）和 5 年生存率（Log-rank χ2 =11.720， HR=3.142，P=0.001）有关，在 K-RAS 野生型中 lincRNA AL390719.2 表达与预后无关（10 年：Log-rank χ2 =1.400，HR= 0.822，P=0.221；5年：Log-rank χ2 =1.997，HR=0.774，P=0.086）。高表达AL390719.2的患者临床分期较晚，容易出现淋 巴结转移和远处转移。结论 lincRNA AL390719.2高表达与K-RAS突变型CRC的不良预后相关，可能是CRC新的 预后标志物和治疗靶点。

关键词: 结直肠肿瘤；预后；基因, ras；基因间长链非编码RNA；K-RAS突变；lincRNA AL390719.2

Abstract: Objective To screen K-RAS mutation related key intergenic non-coding RNAs (lincRNA) in carcinoma of colon and rectum (CRC). Methods RNA-Seq and clinical data from the Cancer Genome Atlas (TCGA) were used to identify K-RAS mutation related lincRNA in CRC. The receiver operating characteristic (ROC) curves were used to analyze the relationship between differentially expressed lincRNA and the 5-year and 10-year survival rates of K-RAS wild-type or mutant patients. The key lincRNA was select. Kaplan-Meier survival curve was used to analyze the impact of the key lincRNA expression on the 5-year and 10-year survival rates of patients. The relationship between the key lincRNA and clinical characteristics was also analyzed. Results A total of 585 cancer tissue samples and 51 normal tissue samples were analyzed for RNA-Seq data. From the data, 6 452 lincRNAs were obtained, of which 85 were up-regulated and 40 were down-regulated. Twelve lincRNAs differentially expressed genes in K-RAS mutants were selected, among which AL390719.2 was the key prognosis lincRNA with K-RAS mutations. Survival analysis results showed that the expression of lincRNA AL390719.2 in the K-RAS mutant was related to the 10-year survival rate (Log-rank χ2 =10.740, HR=3.255, P= 0.002) and 5-year survival rate (Log-rank χ2 =11.720, HR=3.142, P=0.001) of patients. The expression of lincRNA AL390719.2 in the K-RAS wild type was not related to the prognosis (10-year: Log-rank χ2 =1.400, HR=0.822, P=0.221; 5- year: Log-rank χ2 =1.997, HR=0.774, P = 0.086). Patients with high expression of AL390719.2 showed a late clinical stage, and prone to lymph node metastasis and distant metastasis. Conclusion The high expression of lincRNA AL390719.2 is related to the poor prognosis and survival of K-RAS mutant CRC, which may be a new prognostic marker and therapeutic target of CRC.

Key words: colorectal neoplasms, prognosis, genes,ras;long intergenic non-coding RNA, K-RAS mutation, lincRNA AL390719.2